Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs

OBJECTIVES The research and development process in the field of rare diseases is characterised by many well-known difficulties, and a large percentage of orphan medicinal products do not reach the marketing approval.This work aims at identifying orphan medicinal products that failed the developmental process and investigating reasons for and possible factors influencing failures. DESIGN Drugs...

متن کامل

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012

BACKGROUND Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare cancers. In order to provide more insights in drugs for rare neoplastic disorders that are under development and to better understand the role of orphan designation in the develop...

متن کامل

Further peer review failures

Although peer review has been used to maintain the quality of published research, it can be a ‘‘seriously flawed’’ process and might result in the publication of papers with errors. I refer here to the report of a de novo (2;16)(q36.3;p13.3) translocation that is associated with Rubinstein-Taybi syndrome (RTS). This report was published in Clinics and contains a cytogenetic mistake in the depic...

متن کامل

The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children

BACKGROUND Drug development for rare diseases is challenging, especially when these orphan drugs (OD) are intended for children. In 2007 the EU Paediatric Drug Regulation was enacted to improve the development of high quality and ethically researched medicines for children through the establishment of Paediatric Investigation Plans (PIPs). The effect of the EU Paediatric Drug Regulation on the ...

متن کامل

Investigating transition pathways and transition failures and proposing policy solutions to cope with transition failures; Iran’s wind turbine industry

This paper aims to investigate transition paths and reasons of failure of Iran’s wind turbines industry in transition to sustainability successfully. In this regard, a qualitative approach and case study strategy have been used. For this purpose, based on type of national innovation system, the transition path and sustainability transition status of the wind turbines industry in selected countr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: BMJ Open

سال: 2017

ISSN: 2044-6055,2044-6055

DOI: 10.1136/bmjopen-2017-017358